Xie et al. found that p53 wild-type colorectal cancer (CRC) cells were insensitive to erastin, but the sensitivity of these cells to erastin was restored upon inhibition of p53 activity by gene knockout or drugs [56]. This evidence concerns the gene TP53 and colorectal carcinoma.